MNG1124
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.468
- ANGIOGENESIS+0.369
- TNFA_SIGNALING_VIA_NFKB+0.330
- KRAS_SIGNALING_UP+0.314
- COAGULATION+0.221
- INFLAMMATORY_RESPONSE+0.216
- KRAS_SIGNALING_DN+0.205
- ESTROGEN_RESPONSE_LATE+0.193
- IL6_JAK_STAT3_SIGNALING+0.166
- ESTROGEN_RESPONSE_EARLY+0.165
Top 10 suppressed
- DNA_REPAIR-0.374
- WNT_BETA_CATENIN_SIGNALING-0.342
- MYC_TARGETS_V2-0.331
- TGF_BETA_SIGNALING-0.311
- MITOTIC_SPINDLE-0.294
- PEROXISOME-0.280
- NOTCH_SIGNALING-0.259
- ADIPOGENESIS-0.256
- INTERFERON_ALPHA_RESPONSE-0.224
- PI3K_AKT_MTOR_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1147 | — | — | 0.788 |
| 2 | MDT-AP-0005 | Med | Medulloblastoma | 0.755 |
| 3 | SRR1797251 | — | cohortSC | 0.724 |
| 4 | MNG835 | — | — | 0.723 |
| 5 | SRR1486496 | GTEX | — | 0.723 |
| 6 | MNG934 | — | — | 0.721 |
| 7 | MNG874 | — | — | 0.718 |
| 8 | MNG514 | — | — | 0.709 |
| 9 | SRR1516039 | — | — | 0.709 |
| 10 | MNG1061 | — | — | 0.703 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.468 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.369 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.314 | Inavolisib | — uncovered |
| COAGULATION | 0.221 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.216 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.205 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.193 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.166 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.165 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.156 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.155 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.112 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.101 | Inavolisib | — uncovered |
| HYPOXIA | 0.092 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.086 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.067 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.034 | Remibrutinib | — uncovered |